Skip to content

4591.T

RIBOMIC Inc.

グロース · 医薬品 · 医薬品 · JP

JPY 83.00
−5.68%
Ask drillr

Income statement

MetricTTM2026202520242023
Revenue
Total Revenue3.0M2.0M351.9M65.0M
Cost of Revenue
Gross Profit
Operating Expenses
R&D Expense
SG&A Expense399.0M406.1M385.0M351.9M360.8M
General & Admin Expense
Selling & Marketing Expense
Other Expenses
Total Operating Expenses399.0M406.1M385.0M351.9M360.8M
Cost and Expenses275.0M1.2B1.1B1.5B1.9B
Operating Income (EBIT)(1.1B)(1.2B)(1.1B)(1.1B)(1.8B)
Non-Operating
Interest Income5.5M1.7M361.0K1.4M
Interest Expense
Net Interest Income
Other Non-Op Income/Expense25.0M68.6M35.7M133.4M136.7M
Non-Operating Income (excl Interest)2.6M76.6M38.5M136.7M145.7M
EBT (Pre-Tax Income)(1.0B)(1.1B)(1.0B)(1.0B)(1.7B)
Income Tax Expense1.4M1.2M1.2M1.2M1.2M
Bottom Line
Net Income(1.0B)(1.1B)(1.0B)(1.0B)(1.7B)
Earnings from Cont. Ops
Earnings from Discont. Ops
Bottom Line Net Income(1.0B)(1.1B)(1.0B)(1.0B)(1.7B)
Per Share
Basic EPS(¥23)(¥23)(¥25)(¥29)(¥53)
Diluted EPS(¥23)(¥23)
Revenue Per Share¥0¥0¥0¥10¥2
Shares
Basic Shares Outstanding48.1M49.6M40.4M35.7M31.1M
Diluted Shares Outstanding
Profitability Metrics
EBITDA(571.4M)(1.2B)(1.0B)(1.1B)(1.8B)
D&A2.6M4.0M918.0K10.5M480.0K
EBIT(1.1B)(1.2B)(1.1B)(1.1B)(1.8B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026